430 related articles for article (PubMed ID: 30670907)
61. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers.
Vilar-Gomez E; Chalasani N
J Hepatol; 2018 Feb; 68(2):305-315. PubMed ID: 29154965
[TBL] [Abstract][Full Text] [Related]
62. Limitations of Noninvasive Tests-Based Population-Level Risk Stratification Strategy for Nonalcoholic Fatty Liver Disease.
Behari J; Bradley A; Townsend K; Becich MJ; Cappella N; Chuang CH; Fernandez SA; Ford DE; Kirchner HL; Morgan R; Paranjape A; Silverstein JC; Williams DA; Donahoo WT; Asrani SK; Ntanios F; Ateya M; Hegeman-Dingle R; McLeod E; McTigue K
Dig Dis Sci; 2024 Feb; 69(2):370-383. PubMed ID: 38060170
[TBL] [Abstract][Full Text] [Related]
63. CXC Motif Ligand 16 Promotes Nonalcoholic Fatty Liver Disease Progression via Hepatocyte-Stellate Cell Crosstalk.
Jiang L; Yang M; Li X; Wang Y; Zhou G; Zhao J
J Clin Endocrinol Metab; 2018 Nov; 103(11):3974-3985. PubMed ID: 30053055
[TBL] [Abstract][Full Text] [Related]
64. Portal lymphadenopathy predicts non-alcoholic steatohepatitis and advanced fibrosis in non-alcoholic fatty liver disease.
Daher S; Lev Cohen N; Massarwa M; Mahamid M; Nasser M; Hazou W; Oren R; Safadi R; Khoury T
PLoS One; 2018; 13(11):e0207479. PubMed ID: 30500848
[TBL] [Abstract][Full Text] [Related]
65. Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH).
Drescher HK; Weiskirchen S; Weiskirchen R
Cells; 2019 Aug; 8(8):. PubMed ID: 31394730
[TBL] [Abstract][Full Text] [Related]
66. Pathology of non-alcoholic fatty liver disease.
Cataldo I; Sarcognato S; Sacchi D; Cacciatore M; Baciorri F; Mangia A; Cazzagon N; Guido M
Pathologica; 2021 Jun; 113(3):194-202. PubMed ID: 34294937
[TBL] [Abstract][Full Text] [Related]
67. [Histopathological diagnosis and differential diagnosis of nonalcoholic fatty liver disease].
Theurer S; Kälsch J; Schwertheim S; Kathemann S; Baba HA
Pathologe; 2020 Sep; 41(5):434-443. PubMed ID: 32533233
[TBL] [Abstract][Full Text] [Related]
68. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
[TBL] [Abstract][Full Text] [Related]
69. Non-alcoholic fatty liver disease.
Maurice J; Manousou P
Clin Med (Lond); 2018 Jun; 18(3):245-250. PubMed ID: 29858436
[TBL] [Abstract][Full Text] [Related]
70. MicroRNAs in non-alcoholic fatty liver disease: Progress and perspectives.
Hochreuter MY; Dall M; Treebak JT; Barrès R
Mol Metab; 2022 Nov; 65():101581. PubMed ID: 36028120
[TBL] [Abstract][Full Text] [Related]
71. Progression of liver disease in non-alcoholic fatty liver disease: a prospective clinicopathological follow-up study.
Chan WK; Ida NH; Cheah PL; Goh KL
J Dig Dis; 2014 Oct; 15(10):545-52. PubMed ID: 25060399
[TBL] [Abstract][Full Text] [Related]
72. Biopsy and Noninvasive Methods to Assess Progression of Nonalcoholic Fatty Liver Disease.
Bedossa P; Patel K
Gastroenterology; 2016 Jun; 150(8):1811-1822.e4. PubMed ID: 27003601
[TBL] [Abstract][Full Text] [Related]
73. Epidemiology and natural history of non-alcoholic fatty liver disease.
Fazel Y; Koenig AB; Sayiner M; Goodman ZD; Younossi ZM
Metabolism; 2016 Aug; 65(8):1017-25. PubMed ID: 26997539
[TBL] [Abstract][Full Text] [Related]
74. The Role of Noninvasive Tests for Differentiating NASH From NAFL and Diagnosing Advanced Fibrosis Among Patients With NAFLD.
Balakrishnan M; Loomba R
J Clin Gastroenterol; 2020 Feb; 54(2):107-113. PubMed ID: 31789757
[TBL] [Abstract][Full Text] [Related]
75. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.
Newsome PN; Sasso M; Deeks JJ; Paredes A; Boursier J; Chan WK; Yilmaz Y; Czernichow S; Zheng MH; Wong VW; Allison M; Tsochatzis E; Anstee QM; Sheridan DA; Eddowes PJ; Guha IN; Cobbold JF; Paradis V; Bedossa P; Miette V; Fournier-Poizat C; Sandrin L; Harrison SA
Lancet Gastroenterol Hepatol; 2020 Apr; 5(4):362-373. PubMed ID: 32027858
[TBL] [Abstract][Full Text] [Related]
76. AGA Clinical Practice Update on the Role of Noninvasive Biomarkers in the Evaluation and Management of Nonalcoholic Fatty Liver Disease: Expert Review.
Wattacheril JJ; Abdelmalek MF; Lim JK; Sanyal AJ
Gastroenterology; 2023 Oct; 165(4):1080-1088. PubMed ID: 37542503
[TBL] [Abstract][Full Text] [Related]
77. Non-Alcoholic Fatty Liver Disease.
Brůha R
Vnitr Lek; 2019; 65(9):571-575. PubMed ID: 31635468
[TBL] [Abstract][Full Text] [Related]
78. Serum immunoglobulin A concentration is a reliable biomarker for liver fibrosis in non-alcoholic fatty liver disease.
Maleki I; Aminafshari MR; Taghvaei T; Hosseini V; Rafiei A; Torabizadeh Z; Barzin M; Orang E
World J Gastroenterol; 2014 Sep; 20(35):12566-73. PubMed ID: 25253959
[TBL] [Abstract][Full Text] [Related]
79. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis.
Younossi ZM; Loomba R; Anstee QM; Rinella ME; Bugianesi E; Marchesini G; Neuschwander-Tetri BA; Serfaty L; Negro F; Caldwell SH; Ratziu V; Corey KE; Friedman SL; Abdelmalek MF; Harrison SA; Sanyal AJ; Lavine JE; Mathurin P; Charlton MR; Goodman ZD; Chalasani NP; Kowdley KV; George J; Lindor K
Hepatology; 2018 Jul; 68(1):349-360. PubMed ID: 29222917
[TBL] [Abstract][Full Text] [Related]
80. Prevalence and predictors of non-alcoholic steatohepatitis in subjects with morbid obesity and with or without type 2 diabetes.
Lembo E; Russo MF; Verrastro O; Anello D; Angelini G; Iaconelli A; Guidone C; Stefanizzi G; Ciccoritti L; Greco F; Sessa L; Riccardi L; Pompili M; Raffaelli M; Vecchio FM; Bornstein SR; Mingrone G; Gastaldelli A; Capristo E
Diabetes Metab; 2022 Sep; 48(5):101363. PubMed ID: 35760372
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
